Hexarelin

Hexarelin (Examorelin) is a synthetic hexapeptide growth hormone secretagogue that demonstrates unique dual activity: potent GH stimulation through ghrelin receptor activation and distinct cardioprotective effects through CD36 receptor binding. Research shows Hexarelin produces the strongest GH release among the GHRP family peptides, though it is subject to desensitization with prolonged use. The cardioprotective properties are independent of GH release and involve direct effects on cardiac tissue, including improved contractility, reduced apoptosis, and protection against ischemia-reperfusion injury. Studies demonstrate Hexarelin may improve cardiac function in heart failure models and protect against doxorubicin-induced cardiotoxicity. The peptide has been investigated for both growth hormone deficiency and cardiovascular applications. Like other GHRPs, Hexarelin increases appetite and produces modest elevations in cortisol and prolactin. Administration requires subcutaneous injection, and cycling protocols are often recommended to prevent receptor desensitization. The unique cardiac benefits distinguish Hexarelin from other growth hormone secretagogues.

Most human studies are small and short-term; no large randomized trials for functional or long-term outcomes exist; effects on GH output in aging are modest and often require combination strategies; no approved therapeutic use.

Hexarelin is a synthetic hexapeptide growth hormone secretagogue that agonizes the ghrelin receptor (GHS-R1a). In studies it has been given intravenously, subcutaneously, intranasally, and orally; like most peptides it is rapidly degraded, giving a short duration of action.